

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/084,380-Conf. #3496		
		Filing Date	February 28, 2002		
		First Named Inventor	Daniel G. Chain		
		Art Unit	1649		
		Examiner Name	G. S. Emch		
Sheet	1 2	of	1 2	Attorney Docket Number	20555/1203301-US3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	VAN ENGELEN et al., Immunoglobulin treatment in human and experimental epilepsy. J. Neurol. Neurosurg. Psychiatry, 1994, 57(Suppl.):72-75	
	CB	WURSTER et al., Passage of intravenous immunoglobulin and interaction with the CNS. J. Neurol. Neurosurg. Psychiatry, 1994, 57(Suppl.):21-25	
	CC	ZALUTZKY et al., Monoclonal Antibody and F(ab') ₂ Fragment Delivery to Tumor in Patients with Glioma: Comparison of Intracarotid and Intravenous Administration. Cancer Research, 1990, 50:4105-4110	

Examiner Signature	/Gregory Emch/	Date Considered	11/20/2008
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./